Can naltrexone be administered at low doses (low‑dose naltrexone)?

Can Naltrexone Be Taken at Low Doses?

Yes, naltrexone can be administered at low doses (typically 0.5-6.0 mg daily, most commonly 4.5 mg), though this is an off-label use that lacks strong evidence for efficacy and is not addressed in FDA labeling or major clinical guidelines.

FDA-Approved Dosing vs. Low-Dose Use

The FDA-approved dosing for naltrexone is 50 mg daily for alcohol use disorder and opioid use disorder 11. Low-dose naltrexone (LDN) represents off-label prescribing at doses ranging from 0.5-6.0 mg daily, with 4.5 mg being the most commonly used dose 2.

Evidence Quality and Clinical Efficacy

The evidence for low-dose naltrexone is weak and inconsistent:

• A 2026 systematic review found that early positive findings from uncontrolled studies were rarely replicated in placebo-controlled trials 2. Most evidence consists of case reports and small feasibility studies prone to publication bias.

• Real-world data shows limited clinical benefit: In a 2024 study, mean pain scores decreased by only 0.66 points, and 87% of patients discontinued LDN—52% for lack of benefit and 23% for loss of benefit 3.

• Another 2025 Veterans Affairs study showed an average pain score reduction of only -0.83, described as a "small decrease in pain" 4.

Dosing Considerations for Low-Dose Use

If prescribing LDN despite limited evidence:

• Start at 0.5-1.5 mg and titrate upward based on response, as the maximally effective dose is highly idiosyncratic and varies widely between patients 5
• Most protocols use 4.5 mg daily as the target dose 24
• Duration of therapy in studies averaged 123 days 4

Safety Profile

LDN is generally well-tolerated:

• 32% of patients report adverse effects, most commonly vivid dreams, drowsiness, dizziness, and nausea 4
• The medication is inexpensive and has a favorable safety profile 2

Critical Warnings from FDA Labeling

Even at low doses, naltrexone carries important risks:

• Patients must be opioid-free for 7-10 days before starting (longer for buprenorphine/methadone) to avoid precipitated withdrawal, which can be severe enough to require ICU admission 11
• After discontinuation, patients have increased sensitivity to opioids and risk of fatal overdose 11
• Naltrexone can cause hepatotoxicity—monitor liver function 1

Clinical Recommendation

LDN may have a pragmatic role only in treatment-resistant chronic pain cases where standard therapies have failed 2. Before prescribing:

1. Ensure the patient has failed multiple evidence-based therapies
2. Verify the patient is completely opioid-free (including tramadol) for at least 7-10 days
3. Clearly explain the experimental nature and uncertain efficacy
4. Start at 0.5-1.5 mg and titrate based on individual response
5. Set realistic expectations—most patients discontinue due to lack of benefit

The 2022 CDC opioid prescribing guideline mentions naltrexone only in the context of standard-dose (50 mg) medication-assisted treatment for opioid use disorder, not for low-dose pain management 6. This absence from pain management guidelines reflects the lack of robust supporting evidence for LDN in this indication.